Cerep sales flat in the first half

Sales revenues at the French pharmaceutical services firm Cerep were flat during the first half of the year, totalling €14.2 million compared with €14.98 million in the first half of 2007, although at constant exchange rates revenues would have increased by 3.5% to €15.5 million. In vitro ADME activities at its US subsidiary showed a 44.8% increase, while revenues from pharmacological profiling dropped by 5.6% at constant exchange rates. The financial results were affected by budgetary restrictions at some pharmaceutical companies, and by delays in the start of some multiyear collaboration contracts, Cerep says. Consolidated EBITDA from continuing activities was €0.49 million compared with €1.48 million in the previous six-month period. In April, Cerep entered a supply and co-marketing agreement with Perkin Elmer on target screening and profiling services, and in May it opened an additional 10,200 ft2 of laboratories and offices in Redmond, Washington.

Sales revenues at the French pharmaceutical services firm Cerep were flat during the first half of the year, totalling €14.2 million compared with €14.98 million in the first half of 2007, although at constant exchange rates revenues would have increased by 3.5% to €15.5 million. In vitro ADME activities at its US subsidiary showed a 44.8% increase, while revenues from pharmacological profiling dropped by 5.6% at constant exchange rates. The financial results were affected by budgetary restrictions at some pharmaceutical companies, and by delays in the start of some multiyear collaboration contracts, Cerep says. Consolidated EBITDA from continuing activities was €0.49 million compared with €1.48 million in the previous six-month period. In April, Cerep entered a supply and co-marketing agreement with Perkin Elmer on target screening and profiling services, and in May it opened an additional 10,200 ft2 of laboratories and offices in Redmond, Washington.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.